Study reveals link between chickenpox virus in childhood and increased risk of dementia in old age

American researchers have identified that the varicella-zoster virus, which causes chickenpox in childhood, can increase the risk of dementia in old age when it reactivates as herpes zoster.
The study, based on health records from more than 100 million people between 2007 and 2023, showed that multiple episodes of shingles increase the chances of being diagnosed with dementia by up to 9% in the following years.
The analysis, published in the journal Nature Medicine, adjusted data for 400 variables, such as chronic conditions and demographics, and highlighted the preventive role of vaccination.
- Vaccination against herpes zoster reduces risk by 27% to 33% in three years;
- Two doses of Shingrix offer 18% greater protection after five years;
- Women over 80 years old with two doses had a 39% lower risk.
A survey in País of Gales, with 280 thousand adults, confirmed a 20% reduction in the risk of cognitive decline in seven years among those vaccinated.
Virus mechanisms in the brain
The varicella-zoster virus infects most children before the age of 10, remaining latent in nerve ganglia.
With aging or weakened immunity, it can reactivate, causing shingles and inflammation in the central nervous system.
This chronic inflammation affects brain areas linked to memory and cognition, contributing to amyloid plaques similar to those seen in Alzheimer.
Laboratory studies indicate that the virus invades neurons directly or via an excessive immune response, accelerating oxidative damage.
Evidence from recent studies
Analyzes from 2024 and 2025 reinforce the connection between herpesviruses and dementia, with a focus on early infections.
A Swedish survey of elderly people showed that people with antibodies to herpes simplex type 1, common in childhood, double the risk of cognitive decline over 15 years of follow-up.
Data from Taiwan, with national cohorts, showed a 55% reduction in the risk of dementia in patients treated with antivirals after outbreaks of herpes zoster.
Research at Oxford and GSK analyzed millions of records and found consistent patterns of post-reactivation neuroinflammation.
- Recurrent infections increase the hazard ratio for dementia by 1.11;
- Early antiviral treatment cuts incidence by up to 45%;
- Vaccination in adults over 50 prevents 90% of outbreaks.
Impact of vaccination on prevention
The Shingrix vaccine, inactivated and recommended for people over 50 years of age, has demonstrated efficacy in observational studies.
It stimulates a robust immune response, reducing reactivations by 97% and, consequently, brain inflammation associated with dementia.
Compared to Zostavax, withdrawn from the market in 2020, Shingrix offers longer-lasting protection, with visible brain benefits within five years.
In Brasil, the SUS includes the vaccine for immunosuppressed people, and experts advocate expansion for the elderly.
A single dose already reduces the risk by 17%, but the two-dose regimen maximizes the neuroprotective effects.
Additional risk factors
Advanced age accelerates reactivations, with peaks after 60 years due to a drop in cellular immunity.
Carriers of the APOE-ε4 gene, present in 15% of the population, face a doubled risk when combined with latent viral infection.
Diseases such as diabetes and HIV weaken defenses, increasing outbreaks by 30% among those affected.
Longitudinal studies in the US have recorded a 7% cumulative incidence of dementia in unvaccinated people with a history of chickenpox.
Strategies to reduce exposure
Maintaining a healthy lifestyle strengthens the immune system and minimizes viral reactivations.
Regular physical activity, such as 150 minutes of walking per week, improves immune surveillance against herpesviruses.
Diet rich in antioxidants, including fruits and vegetables, combats subclinical inflammation in the brain.
Avoiding chronic stress, via relaxation techniques, prevents cortisol spikes that activate latent viruses.
Annual monitoring at medical appointments allows for early detection of outbreaks and indication of antivirals such as acyclovir.
Repercussions on vulnerable populations
Postmenopausal women show greater susceptibility, with a 35% higher risk in unvaccinated women over 50 years of age.
In tropical regions like Brasil, where 90% of children contract chickenpox, vaccination campaigns could cut 20% of dementia cases projected for 2050.
Studies in Asian cohorts indicate that mixed infections, with herpes simplex, amplify damage by 40%.
Indigenous and rural groups face access barriers, increasing disparities in cognitive health.
Public policies for free immunization integrate viral prevention into the national strategy against Alzheimer.
Advances in global research
2025 Investigations Test Combination Vaccines Against Multiple Herpesviruses for Expanded Brain Protection.
Animal models demonstrate that viral inhibitors reduce amyloid deposits by 25% in infected brains.
Collaborations between GSK and European universities map viral genomes for personalized therapies.
In the southern hemisphere, clinical trials in Brasil evaluate the impact on multiracial populations.
WHO funding prioritizes longitudinal studies to validate causality over 10 years.






